IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors.

ABSTRACT: The accessibility of adoptive T-cell transfer therapies (ACT) is hindered by the cost and time required for product development. Here we describe a streamlined ACT protocol using Th17 cells expanded only 4 days ex vivo. While shortening expansion compromised cell yield, this method licensed Th17 cells to eradicate large tumors to a greater extent than cells expanded longer term. Day 4 Th17 cells engrafted, induced release of multiple cytokines including IL6, IL17, MCP-1, and GM-CSF in the tumor-bearing host, and persisted as memory cells. IL6 was a critical component for efficacy of these therapies via its promotion of long-term immunity and resistance to tumor relapse. Mechanistically, IL6 diminished engraftment of FoxP3⁺ donor T cells, corresponding with robust tumor in

SUBMITTER: Knochelmann HM 

PROVIDER: S-EPMC7501223 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature